Literature DB >> 28779373

Ethical Considerations of Patient-Funded Research for Multiple Sclerosis Therapeutics.

Lilyana Amezcua1, Flavia Nelson2.   

Abstract

Patient-funded research has started to emerge in multiple sclerosis studies, such as low-dose naltrexone and stem-cell therapy. While these represent greater opportunities for the physician, scientist, and patient, ethical concerns concerning protocol review, conflict of interests, and protection of subjects are reviewed.

Entities:  

Keywords:  Ethics; Multiple sclerosis; Patient-funded research

Mesh：

Year:  2017        PMID： 28779373      PMCID： PMC5722765          DOI： 10.1007/s13311-017-0560-9

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN： 1878-7479            Impact factor:   7.620


  34 in total

1.  What makes clinical research ethical?

Authors:  E J Emanuel; D Wendler; C Grady
Journal:  JAMA       Date:  2000 May 24-31       Impact factor: 56.272

2.  Public Awareness of and Contact With Physicians Who Receive Industry Payments: A National Survey.

Authors:  Genevieve Pham-Kanter; Michelle M Mello; Lisa Soleymani Lehmann; Eric G Campbell; Daniel Carpenter
Journal:  J Gen Intern Med       Date:  2017-03-06       Impact factor: 5.128

3.  Ethical challenges in paediatric clinical trials in multiple sclerosis.

Authors:  Silvia N Tenembaum
Journal:  Ther Adv Neurol Disord       Date:  2012-05       Impact factor: 6.570

4.  The Common Rule, Updated.

Authors:  Jerry Menikoff; Julie Kaneshiro; Ivor Pritchard
Journal:  N Engl J Med       Date:  2017-01-19       Impact factor: 91.245

Review 5.  The safety of human pluripotent stem cells in clinical treatment.

Authors:  Oscar E Simonson; Anna Domogatskaya; Pavel Volchkov; Sergey Rodin
Journal:  Ann Med       Date:  2015-07-06       Impact factor: 4.709

Review 6.  Protecting vulnerable subjects in clinical research: children, pregnant women, prisoners, and employees.

Authors:  Karen J Schwenzer
Journal:  Respir Care       Date:  2008-10       Impact factor: 2.258

7.  Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.

Authors:  Richard K Burt; Yvonne Loh; Bruce Cohen; Dusan Stefoski; Dusan Stefosky; Roumen Balabanov; George Katsamakis; Yu Oyama; Eric J Russell; Jessica Stern; Paolo Muraro; John Rose; Alessandro Testori; Jurate Bucha; Borko Jovanovic; Francesca Milanetti; Jan Storek; Julio C Voltarelli; William H Burns
Journal:  Lancet Neurol       Date:  2009-01-29       Impact factor: 44.182

8.  Reproductive issues in women with multiple sclerosis: ethical considerations.

Authors:  Bethanie N Morgan-Followell; Jacqueline A Nicholas; Pedro Weisleder
Journal:  Continuum (Minneap Minn)       Date:  2014-02

9.  Clinical Research in Vulnerable Populations: Variability and Focus of Institutional Review Boards' Responses.

Authors:  Bärbel Kästner; Simone Behre; Nadine Lutz; Friederike Bürger; Steffen Luntz; Katrin Hinderhofer; Martin Bendszus; Georg F Hoffmann; Markus Ries
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

Review 10.  The ethical framework for performing research with rare inherited neurometabolic disease patients.

Authors:  Viviana Giannuzzi; Hugo Devlieger; Lucia Margari; Viveca Lena Odlind; Lamis Ragab; Cinzia Maria Bellettato; Francesca D'Avanzo; Christina Lampe; Linda Cassis; Elisenda Cortès-Saladelafont; Ángels Garcia Cazorla; Ivo Barić; Ljerka Cvitanović-Šojat; Ksenija Fumić; Christine I Dali; Franco Bartoloni; Fedele Bonifazi; Maurizio Scarpa; Adriana Ceci
Journal:  Eur J Pediatr       Date:  2017-01-16       Impact factor: 3.183
View more
  2 in total

1.  Multiple Sclerosis: Unprecedented Progress But Significant Challenges Ahead.

Authors:  Devon S Conway; Le H Hua; Jeffrey A Cohen
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 2.  Retinal stem cell transplantation: Balancing safety and potential.

Authors:  Mandeep S Singh; Susanna S Park; Thomas A Albini; M Valeria Canto-Soler; Henry Klassen; Robert E MacLaren; Masayo Takahashi; Aaron Nagiel; Steven D Schwartz; Kapil Bharti
Journal:  Prog Retin Eye Res       Date:  2019-09-05       Impact factor: 21.198
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.